Ipsen’s Iqirvo wins European approval for primary biliary cholangitis
The European Commission (EC) has conditionally approved Ipsen’s Iqirvo (elafibranor) for the treatment of primary biliary cholangitis (PBC), becoming the…
The European Commission (EC) has conditionally approved Ipsen’s Iqirvo (elafibranor) for the treatment of primary biliary cholangitis (PBC), becoming the…
AstraZeneca's Fasenra (bevacizumab) is set to challenge GSK’s Nucala (mepolizumab) in eosinophilic granulomatosis with polyangiitis (EGPA) as the US Food…
Immunovant has reported positive results from a trial investigating its monoclonal antibody drug batoclimab in Graves’ disease patients, as its…
The atopic dermatitis (AD) market is facing increased growth, with a projected market value of $16.7bn by 2030 for the…
NImmune Biopharma has entered a research partnership with BioTherapeutics, aimed at propelling the development of new precision medicines in the…
Advanz Pharma said it is “considering all options” after the European Commission (EC) revoked Ocaliva’s (obeticholic acid) conditional marketing authorisation.…
Navigator Medicines has secured $100m in a Series A financing round jointly led by RA Capital Management and Forbion to…
The US Food and Drug Administration (FDA) has approved Incyte and Syndax Pharmaceuticals’ antibody therapy, Niktimvo (axatilimab-csfr), as a third-line…
Acelyrin has decided to shake up its pipeline; while the company touted positive Phase III data for izokibep in hidradenitis…
IASO Biotherapeutics has secured US Food and Drug Administration (FDA) approval for its investigational new drug (IND) application for equecabtagene…